Metabolic bone disease in inflammatory bowel disease

Practical Gastroenterology

Volumn 36, Issue 9, 2012, Pages 16-26

  Ghishan, Fayez K ^a   Kiela, Pawel R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CATHEPSIN K; COLECALCIFEROL; DEOXYPYRIDINOLINE; FIBROBLAST GROWTH FACTOR 23; GLUCOCORTICOID; IMMUNOMODULATING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; KLOTHO PROTEIN; LEPTIN; MAGNESIUM; MESALAZINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PYRIDINOLINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR; VANILLOID RECEPTOR 5; VANILLOID RECEPTOR 6; VITAMIN D; VITAMIN K GROUP;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CALCIUM TRANSPORT; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ENTERITIS; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC BONE DISEASE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SCREENING;

EID: 84867539292     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. American journal of physiology. Gastrointestinal and liver physiology 2011;300(2):G191-201.
2. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008;75(10):739-50.
3. Trouvin AP, Goeb V. Receptor activator of nuclear factorkappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010;5:345-54.
4. Uno JK, Kolek OI, Hines ER, Xu H, Timmermann BN, Kiela PR, et al. The role of tumor necrosis factor alpha in downregulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology 2006;131(2):497-509.
5. Majewski PM, Thurston RD, Ramalingam R, Kiela PR, Ghishan FK. Cooperative role of NF-{kappa}B and poly(ADP-ribose) polymerase 1 (PARP-1) in the TNF-induced inhibition of PHEX expression in osteoblasts. J Biol Chem 2010;285(45):34828-38.
6. Thurston RD, Larmonier CB, Majewski PM, Ramalingam R, Midura-Kiela M, Laubitz D, et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology 2010;138(4):1384-94, 1394 e1-2.
7. Huybers S, Apostolaki M, van der Eerden BC, Kollias G, Naber TH, Bindels RJ, et al. Murine TNF(DeltaARE) Crohn's disease model displays diminished expression of intestinal Ca2+ transporters. Inflammatory bowel diseases 2008;14(6):803-11.
8. El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC gastroenterology 2012;12(1):44.
9. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004;53(8):1129-36.
10. Lewis N, Scott B. Guidelines for Osteoporosis in Inflammatory Bowel Disease and Coeliac Disease. In. http://www.bsg.org.uk/ images/stories/clinical/ost_coe_ibd.pdf; 2007.
11. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124(3):791-4.
12. Goodhand JR, Kamperidis N, Nguyen H, Wahed M, Rampton DS. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Alimentary pharmacology & therapeutics 2011;33(5):551-8.
13. Etzel JP, Larson MF, Anawalt BD, Collins J, Dominitz JA. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflammatory bowel diseases 2011;17(10):2122-9.
14. Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, et al. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2007;5(10):1184-9.
15. Kriel MH, Tobias JH, Creed TJ, Lockett M, Linehan J, Bell A, et al. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2010;21(3):507-13.
16. Palomba S, Manguso F, Orio F, Jr., Russo T, Oppedisano R, Sacchinelli A, et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 2008;15(4 Pt 1):730-6.
17. Henderson S, Hoffman N, Prince R. A double-blind placebocontrolled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. The American journal of gastroenterology 2006;101(1):119-23.